Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 19, 1989 - Issue 12
23
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Metabolism of a new dihydropyridine calcium antagonist in rats and dogs

, , , &
Pages 1407-1420 | Received 13 Feb 1989, Accepted 14 Jul 1989, Published online: 30 Sep 2009
 

Abstract

1. The metabolism of a new dihydropyridine calcium channel blocker was studied in rats and dogs. The drug was extensively metabolized by both species after oral dosing. Metabolites were detected by two-dimensional t.l.c. after dosing with the 14C-labelled drug. Urinary metabolite patterns were quantitatively different in rats and dogs.

2. Ten metabolites were isolated from urine, bile and liver homogenate of male or female rats, and identified.

3. The main metabolic pathway was oxidation of the dihydropyridine moiety to the pyridine form, followed by the hydrolysis of the ester, oxidation of the methyl group at the 6-position, and oxidation of the isopropyl group. Other pathways were hydrolysis of the 3-isopropyl ester or 5-methyl ester group to the dihydropyridine monocarboxylic acid (M-2 and M-10, respectively).

4. The drug was metabolized in rats stereoselectively. M-2 and M-10 isolated from rat female urine were analysed by chiral stationary-phase h.p.l.c. and were mainly the enantiomers derived from (-)- and (+)-drug, respectively.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.